Medical disclaimer: This article is for educational purposes only and is not medical advice. TB-500 is not FDA-approved for any human use. No controlled human trials have been completed. Consult a licensed physician before considering any peptide therapy. Never source peptides from unregulated online vendors.
TB-500 is the peptide world’s second-most-discussed healing compound, almost always mentioned in the same breath as BPC-157. But while BPC-157 at least has three small human pilot studies, TB-500’s human evidence base is even thinner — its strongest data comes from horses. This guide covers what the research actually shows, where it falls short, and why physicians urge caution.
For the broader picture, see our peptide dosage chart reference guide and our complete peptide guide for beginners.
What Is TB-500?
TB-500 is a synthetic version of thymosin beta-4, a peptide of 43 amino acids that occurs naturally in virtually all human and animal cells. Its core mechanism: thymosin beta-4 binds to actin, influencing cell migration, proliferation, and differentiation — the fundamental processes of tissue repair. It also promotes angiogenesis.
The Veterinary Research: Decades of Horse Data
Studies on horses using thymosin beta-4 began in the 1960s. Reported effects in horses include significant reduction of inflammation and inhibition of adhesions following injury. After 60 years of animal use, no controlled human trial has been completed.
What Animal Studies Show
- Wound healing: Accelerated closure of skin wounds and reduced scarring in rodent models
- Cardiac repair: Reactivation of cardiac progenitor cells after heart attack in animal models
- Neuroprotection: Promotion of neuronal survival in models of stroke and traumatic brain injury
- Anti-inflammatory effects across multiple tissue types
- Corneal healing in animal models
The Human Evidence: Essentially None
No controlled human clinical trial of TB-500 has been completed. The human “evidence” consists of anecdotal reports from athletes and biohackers, case reports noting mild fatigue, transient headaches, and localized injection-site reactions. With no controlled trials, the absence of documented harms proves nothing about safety.
Safety Concerns Worth Taking Seriously
The most-discussed theoretical risk relates to thymosin beta-4’s anti-apoptotic activity — it helps cells survive that would otherwise undergo programmed cell death. In cancer biology, evasion of apoptosis is one of the hallmarks of malignancy. This has not been demonstrated in humans, but it is a biologically plausible concern that has not been ruled out. TB-500 is not approved by the FDA or any regulatory agency worldwide, and is prohibited by WADA at all times under category S0.
TB-500 vs BPC-157: How They Differ
TB-500 acts systemically and circulates to injured areas, with strongest research in cardiac repair and wound healing (animal). BPC-157 acts more locally with stronger evidence in gut repair and connective tissue healing, and has 3 small human pilots (<30 subjects). Neither is FDA-approved; both are WADA-prohibited. See our full BPC-157 research breakdown.
The Bottom Line
TB-500 has a fascinating mechanism, decades of veterinary use, and genuinely interesting cardiac research. It also has zero completed human trials, an unresolved theoretical cancer concern, and a gray market full of products of unknown quality.
This article is educational content, not medical advice. If you’re exploring peptide therapy, read Peptide Safety: Side Effects and What Doctors Want You to Know and our guide on finding a doctor who prescribes peptides.
Frequently Asked Questions
Are TB-500 and thymosin beta-4 the same thing? Essentially yes. TB-500 is the synthetic version of the naturally occurring thymosin beta-4 peptide.
Is TB-500 legal? It is not approved for human use by any regulatory agency. It is prohibited by WADA for athletes.
Can TB-500 cause cancer? No human evidence links TB-500 to cancer. The concern is theoretical, based on its anti-apoptotic mechanism, and has not been ruled out.
Interested in Peptides?
If you’re interested in exploring peptide therapy, click here to learn more.
